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Abstract Combined D-2- and L-2-hydroxyglutaric aciduria
(D/L-2-HGA) is a devastating neurometabolic disorder, usually
lethal in the first years of life. Autosomal recessive mutations in
the SLC25A1 gene, which encodes the mitochondrial citrate
carrier (CIC), were previously detected in patients affected with
combined D/L-2-HGA. We showed that transfection of defi-
cient fibroblasts with wild-type SLC25A1 restored citrate efflux
and decreased intracellular 2-hydroxyglutarate levels,
confirming that deficient CIC is the cause of D/L-2-HGA. We
developed and implemented a functional assay and applied it to
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all 17 missense variants detected in a total of 26 CIC-deficient
patients, including eight novel cases, showing reduced activities
of varying degrees. In addition, we analyzed the importance of
residues affected by these missense variants using our existing
scoring system. This allowed not only a clinical and biochem-
ical overview of the D/L-2-HGA patients but also phenotype–
genotype correlation studies.
Keywords Mitochondrial citrate carrier . SLC25A1 .
Structure-function correlations . Residue specific score .
Structural homology . Krebs cycle intermediates
Introduction
Combined D-2- and L-2-hydroxyglutaric aciduria (D/L-2-
HGA; OMIM #615182) was described as the third variant of
2-HGA, clinically manifesting a severe phenotype with neona-
tal encephalopathy, respiratory insufficiency, developmental
delay, hypotonia, and early death (Muntau et al. 2000). This
condition is biochemically characterized by accumulation of
both enantiomers of 2-hydroxyglutaric acid (2-HG), with a
more pronounced D-2-HG increase in bodily fluids.
Recessive mutations in the gene SLC25A1 (NM_005984) are
the underlying genetic cause of D/L-2-HGA (Edvardson et al.
2013; Nota et al. 2013). SLC25A1, located on chromosome
22q11, encodes for the mitochondrial citrate carrier
SLC25A1 (CIC). This protein belongs to the SLC25 family
of mitochondrial carriers (MC), which are mainly localized in
the inner mitochondrial membrane and are responsible for the
trafficking of a variety of metabolites (Palmieri 2013; Palmieri
and Monné 2016). All SLC25 members are characterized by a
tripartite structure and topologically by six transmembrane α-
helices (Klingenberg 1989; Kaplan et al. 1993; Palmieri 2013).
The CIC is a protein of 311 amino acids that mediates the
exchange of mitochondrial citrate/isocitrate for cytosolic malate
(Palmieri 2004). Citrate, an important component of energy
metabolism, is mainly produced in the mitochondria end—
to a much lesser extent—in the cytoplasm by reductive
carboxylation (Jiang et al. 2016). Citrate is also taken up
from the blood stream (mainly) via the SLC13A5 sodium-
dependent plasma membrane citrate transporter (Inoue
et al. 2002; Bhutia et al. 2017). The mitochondrial citrate
is either used as an intermediate of the Krebs cycle or
transported outside the mitochondria by the CIC, where it
plays important roles in fatty acid and sterol synthesis,
regulation of glycolysis, histone acetylation, and other
physiopathological processes (Mycielska et al. 2009;
Iacobazzi and Infantino 2014).
When the CIC function is impaired, it is presumed that mito-
chondrial citrate accumulates, and as a result, cytosolic citrate
concentration decreases (Nota et al. 2013). Studies of primary
deficient fibroblastsgrownin[U-13C6]glucose-enrichedmedium
showed lower [13C2] citrate levels in culturemedium than in con-
trols (Nota et al. 2013). Also, individuals with mitochondrial cit-
rate deficiency have D/L-2-HGA and, as a group, lower urinary
levels of citrate (and, to some extent, also isocitrate), and higher
urinary levels ofKrebs cycle intermediates downstreamof citrate
(α-ketoglutarate,succinate, fumarate,andmalate)comparedwith
controls (Nota et al. 2013; our study, Supplementary Table 1).
Fourteen genetically confirmed cases with combined D-2-
and L-2- HGA have been reported with varying, usually severe,
clinical presentation (Muntau et al. 2000; Read et al. 2005;
Edvardson et al. 2013; Nota et al. 2013; Mühlhausen et al.
2014; Prasun et al. 2015; Smith et al. 2016). Two additional
cases (a sibling pair) associated with SLC25A1 deficiency pre-
sented amilder clinical phenotypewith impaired neuromuscular
transmission and no HGA (Chaouch et al. 2014).
To date, 16 mutations throughout the SLC25A1 gene have
been reported (Edvardson et al. 2013; Nota et al. 2013; Prasun
et al. 2015; Smith et al. 2016). Most (75%) described muta-
tions are missense. Analysis of missense variants by common-
ly used software prediction tools is a challenge. We applied
the scoring system for SLC25 members (Pierri et al. 2014)
to characterize the importance of the involved individual
amino acids. In addition, we developed and implemented a
functional assay for analysis of the SLC25A1 missense
variants, followed by genotype–phenotype studies.
Materials and methods
Patients, clinical and biochemical data
Inclusion criteria for this study were the presence of SLC25A1
variants and combined D/L-2-HGA; 26 individuals were evalu-
ated. Clinical data was collected from referring physicians using
questionnaires. For previously published case reports (Muntau
et al. 2000; Read et al. 2005; Edvardson et al. 2013; Chaouch
et al. 2014; Mühlhausen et al. 2014; Prasun et al. 2015; Smith
et al. 2016), datawas completed by twoof our authors (MW,AP)
basedonpublished information.Noclinical data couldbeobtain-
ed for patient nos. 2 and 26 (sibling of patient no. 3). The D/L-2-
HGA biochemical diagnosis was, in most cases (N = 22),
established by our laboratory using liquid chromatography tan-
demmass spectroscopy (LC-MS/MS)measurements ofD-2-HG
andL-2-HG inurine, as previouslydescribed (Struys et al. 2004),
or theinformationwascollectedviaquestionnaires(N=1)orfrom
literature (N= 3; two of threewere reported not to have increased
urinary D-2-HG and L-2-HG) (Chaouch et al. 2014).
Genetic testing
For seven of the unpublished D/L-2-HGA-affected individ-
uals, all exons and adjacent splice sites of the SLC25A1
coding region were amplified by polymerase chain reaction
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(PCR), as previously described (Nota et al. 2013).
Sequencing analysis was performed using an ABI 3130xl
genetic analyzer (Applied Biosystems, Nieuwekerk a/d
Ijssel, NL), and data was interpreted using Mutation
Surveyor (Softgenetics, PA, USA). Whole-exome sequenc-
ing, followed by direct Sanger sequencing, resulted in the
genetic diagnosis in another affected individual.
Construction of the expression vector and site-directed
mutagenesis to introduce missense variants
The coding sequence of the SLC25A1 gene was recloned from
pCMV6-AC-GFP (Origene, Rockville, MD, USA) into the
pEGFP-N1 vector (Clontech). Subsequently, the enhanced
green fluorescent protein (EGFP) was removed from the vec-
tor, as it interfered with protein function. For each of the 17
missense mutations included in this study, recombinant plas-
mids were generated by site-directed mutagenesis, as previ-
ously described (Betsalel et al. 2012). Successful mutagenesis
and absence of PCR artifacts was confirmed by full-length
sequencing of the SLC25A1 coding sequence.
Restoration of the primary defect and overexpression
studies
SLC25A1−/− fibroblasts from patient 9, homozygous for
c.18_24dup; p.Ala9Profs*82 mutation, were transfected with
wild-type SLC25A1 (wt), empty vector or mock transfected,
by electroporation using 4D–Nucleofector™ system and P2
primary cell kit (Lonza, Cologne, Germany), following the
manufacturer’s guidelines. Thereafter, the 17 SLC25A1 con-
structs were transiently transfected in SLC25A1−/− fibroblasts
using 1.5 million cells per condition. The pEGFP-N1 was
cotransfected with the CIC-expressing vectors (with or
without the introduced variants) in a ratio of 1 to 100. All
experiments were performed in triplicate.
Functional studies
Twenty-four hours after transfection, cells were incubated for
48 h with Dulbecco’s modified Eagles medium (DMEM)
enriched with [U-13C6] glucose. Thereafter, culture media
and cell pellets were collected and stored at −20 °C and
−80 °C, respectively. To assess restoration of the CIC function
in wild-type transfectants and activity of mutated proteins,
[13C2] citrate levels in cell culture media of transfected
fibroblasts were used, as previously described (Nota et al.
2013). The percentage of residual CIC activity is expressed
to the activities of wild-type transfectants, which were arbi-
trarily set at 100% in each experiment.
Confirmation of successful transfection by Western
blotting
Transfected cells were subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blot analysis. First, cells were lysed in urea lysis
buffer (8 M urea, 100 mM NaCl, 10 mM Tris-HCl, pH 8.0)
and sheared through an insulin syringe needle for DNA dis-
ruption. Protein content was determined using a bicinchoninic
acid protein assay (Sigma-Aldrich, St Louis, MO, USA).
Proteins (17 μg) were size-separated in a 12% NuPAGE®
Bis-Tris precast gel (Invitrogen, Carlsbad, CA, USA) and
transferred to a polyvinylidene fluoride (PVDF) membrane
using the iBlot® Dry Blotting System (Invitrogen).
Immunodetection of the SLC25A1 protein was carried out
using rabbit polyclonal anti-SLC25A1 primary antibody
(Proteintech, 15,235–1-AP), polyclonal goat anti-rabbit
immunoglobulins/horseradish peroxidase (HRP) secondary
antibody (Dako, P 0448) and enhanced chemiluminescent
substrates (Lumi-Light plus Western blotting substrate;
Roche Applied Science, Indianapolis, IN, USA). Images were
acquired with the ChemiDoc MP imager (Bio-Rad
Laboratories) and analyzed using Image Lab software. Actin
was used as an internal loading control.
Residue-specific scores of mutated residues
Using the scoring systems developed by Pierri et al. 2014,
functional and/or structural importance of mutated residues
was evaluated. The residue-specific score (RS) estimates
the strength of the evolutionary selection on each amino
acid residue of an individual mitochondrial carrier.
Considering all 216 residues previously scored for
SLC25A1 (Pierri et al. 2014), a residue with an RS > 4.68
is above the median value and therefore considered func-
tionally and/or structurally important in the human CIC. A
transversal score (TS) was calculated by averaging the 53
residue-specific scores corresponding to equivalent posi-
tions identified by the multialignment of the 53 members
of the human mitochondrial carrier protein family (MCF),
using the Bos taurus protein BtAAC1 structure as reference.
A residue with a TS > 3.79 is above the median value and
considered functionally and/or structurally important in the
common MCF structure and transport mechanism.
Structural homology model of the human CIC
The homology model of human CIC (residues 23–299) was
made with MODELER (Fiser and Sali 2003) based on the X-
ray structure of the bovine adenosine diphosphate/adenosine
triphosphate (ADP/ATP) carrier (Pebay-Peyroula et al. 2003).
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Results
SLC25A1 gene sequencing results
An overview of all 22 mutations found in the SLC25A1 gene,
including six novel, is given in Fig. 1. Most of these mutations
are private, and only seven mutations were found in more than
one patient. The most frequent mutation is p.Ala9Profs*82,
detected in five patients (four apparently unrelated families).
Presentation and clinical features
Presenting symptoms are summarized in Table 1. Dysmorphic
features seen more than once are prominent forehead–frontal
bossing in four patients, bitemporal hypoplasia–midface hy-
poplasia in three, hypertelorism in four, and down-slanting
eyes in three. A low or flat nasal bridge was seen in four,
low-set or rotated ears in three, abnormal thumbs in two,
micrognathia in three, and retrognathia in two. Head circum-
ference was normal in seven; six patients were microcephalic
and one macrocephalic. Weight was normal in ten, and four
patients had growth retardation. Delayed motor milestones
were reported in 16 patients, with no development at all in
two patients.Motor function evaluation was not determined or
given in seven cases. Cognitive development was impaired in
13 patients, and no development was observed in three. No
specific tests were performed to evaluate cognition. Other
specific abnormalities are optic atrophy, seen in patient 1, a
feature described previously by Edvardson et al., in patient 22.
At follow-up, epilepsy becomes a more prominent feature.
Seizures were seen clinically or on electroencephalogram
(EEG) in 20 patients, apnea was reported as seizure in three
cases. Four patients showed no seizures, but this was on the
grounds of a normal EEG during apneic attacks. Radiographic
information from magnetic resonance imaging (MRI), com-
puted tomography (CT scan), or brain ultrasound (US) inves-
tigations showed brain atrophy and/or ventriculomegaly in 14
of 20 patients and corpus callosum hypoplasia or dysplasia in
12 of 20. Germinolytic cysts or germinal matrix cysts were
seen in two patients. Bilateral frontal lobe cysts, evidence of
prenatal intraventricular bleeding, and cerebellar hypoplasia
and gliotic hyperintensity of frontal white matter were seen
separately in individual cases. Brain MRI of patient 24 was
normal (Chaouch et al. 2014). Initial laboratory findings re-
vealed lactic acidosis in 14 of 17 cases. Urinary levels of
Krebs metabolites of seven of eight unpublished patients are
shown in Supplementary Table 1.
Restoration of CIC function by overexpression
of wild-type SLC25A1
Transfection of SLC25A1−/− fibroblasts with wild-type
SLC25A1 not only restored SLC25A1 levels, as detected
by immunoblotting (Fig. 2a), but also resulted in the
expected increase of citrate efflux (by > 3-fold compared
with cells transfected with an empty vector) (Fig. 2b),
accompanied by decreased intracellular D-2-HG and L-
2-HG levels (Fig. 2c).
Fig. 1 SLC25A1 gene showing distribution of all currently known
mutations. These mutations are part of the mutations database LOVD
(http://www.lovd.nl/slc25a1). Novel mutations described in this study
are represented in bold
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Functional studies: genotype–phenotype correlations
Residual activities of studied missense variants varied from
almost 0 to 85% of that of wild-type transfectants. Patients
with a severe clinical outcome—death before 1 year and/or
intensive medical care—had missense variants with residual
activities up to 23% and/or severe truncating mutations (i.e.,
nonsense or frameshift), considered to result in no CIC activ-
ity. Therefore, by using the 25% residual activity as cutoff
value, we divided the D/L-2-HGA patient cohort into three
groups: (1) patients with two severely affected CIC alleles
(truncating or missense mutations with < 25% residual activ-
ity); (2) patients compound heterozygous for a severely and a
mildly affected allele; (3) patients with two relatively mildly
affected CIC alleles (with residual activity > 25%).
In group 1, we included four patients carrying two truncat-
ing mutations and eight (nos. 3, 6, 8, 16, 17, 18, 22, and 23)
with missense variants showing severe impairment of the CIC
function (< 25%; Table 1). Five of these missense variants
were detected in patients in homozygous form: c.844C > T;
p.Arg282Cys (patient 3), (c.139G > A; p.Glu47Lys (patient
16); c.278G > A; p.Gly93Asp (patient 17); c.430G > C;
p.Glu144Gln (patient 8), and c.593G > A; p.Arg198His (pa-
tient 18). The first four of these five patients presented with a
rapidly progressing, severe phenotype associated with early
death before 1 year of age (Table 1). The fifth patient (patient
18), homozygous for c.593G > A; p.Arg198His that had an
early onset with severe clinical signs, was completely care
dependent but was alive at the age of 5 years (Smith et al.
2016). Three of the eight group 1 patients with missense var-
iants were compound heterozygous: c18_24dup;
p.Ala9Profs*82 and c134C > T; p.Pro45Leu (sibling patients
6 and 23); c.389G > A; p.Gly130Asp and c.845G > A;
p.Arg282His (patient 22). The latter (also described by
Edvardson et al. 2013) presented with a severe phenotype as
well, being the first CIC patient described with agenesis of
corpus callosum and optic nerve hypoplasia. The four patients
(nos. 7, 9, 13, and 14) with truncating mutations also had a
severe phenotype and died before 1 year of age. Patients 2 and
26 (sibling of patient 3) should also be included in group 1, as
they were homozygous for the severe c.844C > G;
p.Arg282Gly and c.844C > T; p.Arg282Cys missense muta-
tion, respectively. However, no clinical data could be obtained
to confirm this.
The four patients of the second group of SLC25A1-
deficiency (nos. 5, 19, 21, and 12) were all compound hetero-
zygous for a severe and a mild allele. Patient 5 was compound
heterozygous for missense substitution c.499G > A;
p.Gly167Arg (49% activity) and the p.Ala9Profs*82 muta-
tion, which could explain the relatively severe phenotype of
the patient, which was associated with death before 2 years of
age. Patient 19 was compound heterozygous for a novel frame
shift mutation, c.648_655del; p.Met218Serfs*25 and theb I
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c.119 T > A; p.Ile40Asn (34% activity). Despite the poor
clinical condition of a persistent vegetative state and being
dependent on mechanical ventilation and tube feeding, patient
19 was alive (23 months) at the time of the questionnaire;
citrate treatment was started at 3 months of age at 800 mg/
kg per day, and since then, fewer cerebral attacks were regis-
tered. The c.844C > T; p.Arg282Cys missense variant (5%
residual activity) was not only detected in the homozygous
form in patient 3 (patient group 1) but also in patient 21,
compound heterozygous with the c.605 T > C; p.Met202Thr
variant (66% activity). The latter was also heterozygous in
patient 10 of group 3. Patient 21 had a milder phenotype than
patient 3, probably explained by the fact that the second allele
of patient 21 harbored a missense variant with high residual
CIC activity. Interestingly, this patient also presented clinical
features of a myasthenia crisis during respiratory arrest events,
precipitated by intercurrent illness. Supplementation with cit-
rate at 800 mg/kg per day prevented any further need for
hospitalization during febrile illnesses. The last patient in this
group, patient 12, was compound heterozygous for a frame-
shift mutation and the c.821C > T; r.[821c > t, 820_821del]
mutation, involving a splice site. This splice mutation, which
mainly results in expression of the frameshift transcript (r.
820_821del; p.Ala274Ilefs*24), may also result in some au-
thentic spliced transcript containing a missense variant
(p.Ala274Val; Nota et al. 2013, unpublished data). To inves-
tigate the activity of this potential minor transcript r.821c > t
(p.Ala274Val), we studied this variant as well, which had 85%
residual activity. Patient 12 is the first patient for which the
effects of citrate treatment on the clinical course are described
in detail (Mühlhausen et al. 2014).
The third group of D/L-2-HGA patients included six cases
(five unrelated families), of which four were homozygous (nos.
1, 15, 24, and 25) and two compound heterozygous (nos. 10 and
20). We detected six missense variants with residual activities
ranging from 30 to 71% of the activity of wild-type
transfectants. The c.578C > G; p.Ser193Trp (31% activity)
was detected in two unrelated patients: in homozygous form
in patient 1 and heterozygous form in patient 20. Patient 1 was
21 months old at the date of receiving the completed question-
naire, and had early symptom onset at 10 days of age. The
patient underwent intermittent respiratory support via continu-
ous positive airway pressure (CPAP) through tracheostomy.
Patient 20, aged 3 years, was compound heterozygous for the
c.578C > G; p.Ser193Trp and the c.82G > A; p.Ala28Thr var-
iant (71% activity). By comparison, the phenotype of patient 1,
homozygous for the c.578C > G; p.Ser193Trp variant, was
more severe than that of patient 20. Based on this observation,
we speculate that compound heterozygosity of this variant with
a higher residual activity missense variant represents an advan-
tage for clinical course and severity of the disease. A similar
correlation was observed for patient 10, who was compound
heterozygous for the c.605 T > C; p.Met202Thr (66% activity)
and c.890A > G; p.Tyr297Cys (30% activity); this patient died
at the age of 11 years with typical manifestations of D/L-2HGA.
Patients 10 and 20 had a milder clinical phenotypes and were
not dependent on mechanical ventilation; tube feeding was only
occasionally needed. For patient 20, citrate treatment was initi-
ated at 9 months of age at a dosage of 1500 mg/kg per day and
resulted in developmental gains, improved muscle tone, and
absence of clinical seizures and apneic events. The effect of
citrate treatment in patient 10 cannot be properly assessed be-
cause of the very late start in the disease course (at 10.5 years of
age) and the very short duration of the trial (1 or 2 weeks,
respectively). The homozygous variant, c.740G > A;
p.Arg247Gln (52% activity), was present in an adult sibling pair
(patients 24 and 25) with a very mild, atypical phenotype, sug-
gestive of congenital myasthenia syndrome (Chaouch et al.
Fig. 2 Restoration of mitochondrial citrate carrier (CIC) function by
overexpression of wild-type SLC25A1 in SLC25A1
−/−
fibroblasts. a
Detection of overexpressed protein by Western blotting. b [
13
C
2
] citrate
levels measured in culture medium by liquid chromatography tandem
mass spectroscopy (LC-MS/MS) show increased levels in wild-type
transfectants compared with empty and mock transfectants. Horizontal
lines indicate the group sample mean (n = 3). c Mean D-2-
hydroxyglutaric acid (HG) and L-2-HG intracellular levels (standard de-
viation). The abundance of formed L-2-HG and D-2-HG isotopomers
were so low that quantification was hampered; however, unlabeled L-2-
HG and D-2-HG were quantifiable, and these values are depicted here
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2014). Patient 15 was homozygous for c.784 T > C;
p.Cys262Arg variant, which displays 48% residual activity.
Intriguingly, despite the relatively high residual activity, this
patient presented a severe clinical phenotype of CIC deficiency,
with abnormal brain MRI findings and recently developed clin-
ical seizures. This patient (2 years of age) was dependent on
intensivemedical support. However, he was able to have breath-
ing sprints off the ventilator for 8 h per day, during which time
his pulse oximetry remained > 93% on room air. Otherwise, he
was ventilator-dependent without the need of supplemental ox-
ygen. In addition to the patients discussed above, two apparently
unrelated patients (nos. 4 and 11) were included in this group. In
both, the above described c.821C > T mutation (r.[821c > t,
820_821del]) was detected in homozygous form.
Location of missense mutations in the CIC structural
homology model
Positions ofmissensemutations weremapped onto the homol-
ogy model of CIC (Fig. 3). It is noteworthy that all residues
affected by these missense substitutions have a TS above the
threshold of 3.79 (Supplementary Table 2), with the exception
of alanine 28, with a TS of 3.40; it also has the highest residual
activity of all the disease-causing CIC mutations (Table 1).
This observation, together with the fact that various
inactivating mutations have been reported at corresponding
sites in other MC (Abrams et al. 2015; Ma et al. 2007;
Palmieri 2014; Shamseldin et al. 2016; Thompson et al.
2016); (Supplementary Table 2), indicates that these muta-
tions affect residues important in the common structural and
functional features of MCF and potentially lead to impaired
transport activity.
The single mutations of patients in group 1 are found in
functionally important locations within the CIC protein: (1) in
the area of the substrate-binding site, consisting of residues in
the contact points on each of the three even-numbered trans-
membrane helices (Robinson and Kunji 2006) and residues in
the vicinity of the contact points that also contribute to deter-
mine substrate specificity (Marobbio et al. 2008; Monné et al.
2012); (2) in the 3-fold repeated and highly conserved signa-
ture motif sequence PX[D/E]XX[K/R]X[K/R]X20–
30[D/E]GXXXX[W/Y/F][K/R]G (PROSITE PS50920,
PFAM PF00153 and IPR00193), found in members of the
mitochondrial carrier family (Palmieri 1994). Here, prolines
and first glycines are located in the odd- and even-numbered
transmembrane helices, respectively, on the matrix side of the
substrate-binding site, constituting the so-called proline–gly-
cine (PG) level 2, implicated in opening and closing the matrix
gate of the central substrate translocation pore (Palmieri and
Pierri 2010a, b); (3) at PG level 1, where prolines and glycines
are found in even- and odd-numbered transmembrane helices
on the intermembrane space side, and are suggested to
participate in opening and closing the cytoplasmic gate
of the central substrate translocation pore (Palmieri and
Pierri 2010a, b). It is also noteworthy that all residues
affected by these missense substitutions are located in
positions with high RS. All RSs of group 1 patients rang-
ing from 5.04 (Glu144Gln) to 6.07 (Arg198His) are above
the threshold of 4.68, indicating that these mutations af-
fect residues important in the CIC (Table 2), in keeping
with the observed functional data.
All residues affected by missense substitutions of groups 2
and 3 are found within the CIC protein: (1) inside the carrier
cavity but not in the substrate binding area, with one excep-
tion; i.e., isoleucine 40; (2) outside the substrate translocation
pore toward the membrane and at PG level 1; (3) on the out-
side of the matrix gate. They all have RSs above the threshold
of 4.68, except for alanine 28, with the lowest RS (3.34),
which corresponds to the highest residual activity of all
disease-associated CIC mutations (71% of WT); arginine
247 with a RS of 3.38, and isoleucine 40 with a RS of 3.50.
The latter residues display substantial residual transport activ-
ity (52% and 34%, respectively) (Table 2).
Discussion
We present an overview of the clinical phenotypes of 26 ge-
netically diagnosed D/L-2-HGA patients, including eight nov-
el cases. To make a first prediction for clinical outcome, we
classified patients into three groups based on their phenotype
and genotype, as described in the BResults^ section: (1) two
severe alleles (with < 25% residual activity), (2) one severe
and one mild allele, and (3) two mild alleles. The importance
of mutated residues is evaluated using the scoring system
developed by Pierri et al. and by the newly developed func-
tional studies.
A detailed discussion on the different mutations and their ac-
tivities and classification in the three groups is provided in the
supplementary data (Palmieri et al. 2011; Ruprecht et al. 2014;
vonHeijne 1996).
This study provides a first observation that a genotype–
phenotype correlation exists in this small cohort of patients
with D/L-2HGA. Lack of residual SLC25A1 transporter ac-
tivity (severe missense mutation or truncating mutation) is
likely to contribute to a severe disease presentation associated
with early death. We also noted a strong positive correlation
between extensive medical care and increased life expectancy,
irrespective of type of mutation/residual activity. This may
partly be explained by altering the natural history of the dis-
ease by preventing apneic episodes, aspiration risk, and respi-
ratory arrest by ventilation support and improving metabolic
status by improved nutrition through g-tube feeding. It is of
interest to note that there is an alternative route for citrate
production in the cytoplasm by reductive carboxylation
(Jiang et al. 2016), which may explain the presence of some
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residual citrate levels. However, this is apparently not suffi-
cient to prevent illness. Identifying functionally important res-
idue positions in MC by RS, introduced by Pierri et al. 2014,
has proven to be very valuable in classifying missense
mutations in CIC (Table 2). All mutated residues with RSs
below the threshold value correspond to mutant proteins with
considerable residual activity (p.Ala28Thr, p.Arg247Gln and
p.Ile40Asn). However, there is no direct relationship between
Fig. 3 Homology model of
human mitochondrial citrate
carrier (CIC). The model is
displayed with rainbow colors
from the N-terminus (N blue) to
the C-terminus (C red). Mutated
residues are shown as spheres,
with carbons in magenta.
a Carrier from the lateral side (in
the membrane plane) with the in-
termembrane space side on the
top and the mitochondrial matrix
side on the bottom. b Cavity of
the carrier as viewed from the in-
termembrane space side
Table 2 Correlation between average activity, missense alleles, residue-specific scores, and clinical severity
Patient ID Missense
allele 1
Activity
(%)
Other allele Average
activity (%)
Residue-specific scorea Clinical
severityb
Patient
group
8 Glu144Gln 1 homozygous 1 5.04 severe 1
3 (26) Arg282Cys 5 homozygous 5 5.61 severe (no data) 1
2 Arg282Gly 7 homozygous 7 5.61 no data 1
17 Gly93Asp 7 homozygous 7 5.5 severe 1
16 Glu47Lys 8 homozygous 8 5.27 severe 1
22 Arg282His 1 Gly130Asp 8.5 5.61/5.50 severe 1
22 Gly130Asp 16 Arg282His 8.5 5.50/5.61 severe 1
18 Arg198His 11 homozygous 11 6.07 severe 1
6 (23) Pro45Leu 23 frame shift 11.5 5.0/fs severe (severe) 1
19 Ile40Asn 34 frame shift 17 3.50/fs severe 2
5 Gly167Arg 49 frame shift 24.5 5.10/fs severe 2
1 Ser193Trp 31 homozygous 31 5.51 mild 3
21 Arg282Cys 5 Met202Thr 35.5 5.61/5.33 mild 2
21 Met202Thr 66 Arg282Cys 35.5 5.33/5.61 mild 2
10 Tyr297Cys 30 Met202Thr 48 4.89/5.33 mild 3
15 Cys262Arg 48 homozygous 48 5.51 severe, but intermittent ventilation 3
20 Ala28Thr 71 Ser193Trp 51 3.34/5.51 mild 3
24 (25) Arg247Gln 52 homozygous 52 3.38 mild 3
a Residue-specific scores (RS) are a measure of the strength of the evolutionary selection acting on the carrier residues and, hence, of their function and
structure relevance. RS scores > 4.68 indicate that the affected residues are considered functionally relevant and/or structurally important. Lower scores
are only observed for mutant proteins with considerable residual activity, indicated in bold (p.Ala28Thr, p.Arg247Gln and p.Ile40Asn)
bMild phenotype compared with the severe combined D/L-2-hydroxyglutaric aciduria (HGA) cases
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RS above the threshold and the level of transport activity of a
mutated protein, because their activity not only depends on the
structural/functional importance of the original residue but
also on the kind of substitution: changes in side-chain size,
charge, etc. Nevertheless, RSs > 5.6 are associated with mu-
tant proteins with a very low residual activity (≤11% of wild
type).
It should be noted that our study has some limitations. First,
our functional assay is a steady-state measurement of [13C2]
citrate accumulation in extracellular medium after prolonged
culture with [U-13C6] glucose and is an indirect activity mea-
surement, most likely overestimated, and proxy of actual cit-
rate transport activity of a single allele across the inner mito-
chondrial membrane in vivo. Second, our assay cannot simul-
taneously measure the activity of two alleles, meaning that it
does not allow us to mimic compound heterozygous patients,
where the degree of CIC functional deficiency is the result of
the contribution of both alleles. Although it is not known
whether increased expression levels of both or one allele in
cells of compound heterozygous patients might in part com-
pensate for low-activity mutant proteins, activity in these cells
can be estimated by averaging the activity levels measured
separately for both alleles. By doing so, we observed that in
the case of compound heterozygosity also, an in vitro activity
< 25% of wild-type transfectants can be associated with a
more severe phenotype (Table 2).
In conclusion, our newly developed functional assay can be
used, together with structural data and residue-specific scores,
as an assisting tool for interpreting new missense variants and
may be of added value for physicians in counseling parents of
patients with (missense) variants in CIC.
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